I

Inspire Medical Systems

FDA-approved neurostimulation device for OSA

Prior Authorization Specialist

Full-TimeUpdated
$50k - $70k+ Equity awards + Employee Stock Purchase Program
Junior
Bachelor's
Golden Valley, MN, USA
RemoteFully remote position.
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • At least 2 years of related work experience in reimbursement.
  • Demonstrated knowledge of reimbursement compliance requirements and ability to promote a compliant reimbursement environment with personal integrity.
  • Ability to read, interpret, and appropriately respond to payer requirements relating to prior authorization.
  • Ability to read, interpret, and summarize clinical and cost literature.
  • Proficiency in Microsoft Office applications, including Word, PowerPoint, and Excel.
  • Bachelor’s degree preferred.
  • Medical device experience preferred.
Responsibilities
  • Support the Prior Authorization Program by entering and managing patient information in a database, assisting with patient intake and insurance coverage verification, calling insurers to obtain the status of prior authorization requests, and working with patients and sites to pursue authorization success.
  • Track and monitor prior authorization requests and related appeals through to External Medical Review (EMR).
  • Participate in updating materials and best-practice methods supporting prior authorization and appeals processes, including EMR for upper airway stimulation.
  • Seek continuous process improvement to increase success rates and reduce time to success.
  • Implement the Prior Authorization Program by training sites on program requirements, completing prior authorization requests, providing participating sites guidance on all levels of appeals including EMR, and working directly with patients to pursue EMR success.
  • Provide general coding information to physician customers upon request.
  • Work with the manager and staff to execute action plans and objectives supporting internal and external clients.
  • Document product- and therapy-related field reports within prescribed timelines, provide documents needed to complete investigations, and submit follow-up reports as needed.
  • Complete required training and competency confirmations within required timelines.
  • Comply with applicable quality system procedures and policies, and suggest continuous process improvements.
Desired Qualifications
  • Medical device experience.

About the company

I

Inspire Medical Systems

View

Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Golden Valley, Minnesota

Founded

2007

Get referred to Inspire Medical Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 Project Horizon targets $30 million annualized investment capacity by 2027.
  • September 2026 conference materials said coding clarity improved and WISeR-state billing issues eased.
  • CMS proposed 2027 facility-rate increases of 12% to 15%, supporting procedure economics.

What critics are saying

  • The January 2026 class action alleges Inspire V launch failures and misleading disclosures.
  • Medicare coding disruption cut second-quarter revenue $40 million; management expects $120 million-$130 million full-year impact.
  • If reimbursement stalls again before 2028 CPT approval, Inspire's growth thesis breaks quickly.

What makes Inspire Medical Systems unique

  • Inspire remains the only FDA-approved hypoglossal nerve stimulator for moderate-to-severe OSA.
  • The 2026 launch of Inspire V strengthened procedure simplicity and 3.0T MRI compatibility.
  • Direct U.S. sales and distributor coverage give Inspire tight control over adoption and education.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Tuition Reimbursement
  • Employee Assistance program
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 30th, 2026
Monolithic Power and Medpace make our watchlist; Inspire Medical's $898.7M revenue raises concern

StockStory has named two high-flying stocks to watch and one to avoid, warning that expensive shares leave little room for error. It advises selling Inspire Medical Systems (NYSE:INSP), which makes an implantable device for obstructive sleep apnea. Revenue of $898.7 million is subscale, and it forecasts a 3.4% decline over the next 12 months. The shares trade at $69.10, or 52.2x forward earnings. Monolithic Power Systems (NASDAQ:MPWR), a power management chipmaker, grew revenue 27.6% a year over five years. Earnings per share rose 29.9% a year. Its $1,191 share price equals 35.9x forward earnings. Medpace (NASDAQ:MEDP), a clinical trial services provider, averaged 18.7% organic revenue growth over two years. It trades at $663.33, or 35.7x forward earnings.

Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 7th, 2026
Inspire Medical shares surge 28.1% after Q2 earnings beat and raised 2026 guidance

Inspire Medical Systems shares have risen 28.1% in the past month following a second-quarter earnings beat and raised 2026 guidance. The company reported adjusted earnings of 14 cents per share, surpassing consensus estimates for a 22-cent loss, whilst revenues of $200.6 million exceeded expectations despite declining 7.6% year over year. Management increased its 2026 revenue outlook to $835–875 million and raised adjusted earnings guidance to $1.05–$1.45 per share. The Zacks consensus estimate for 2026 earnings increased 34.7% over the past four weeks. However, coding challenges and prior authorisation programmes reduced second-quarter revenues by approximately $40 million. Management expects a full-year impact of $120–130 million and forecasts an 8–10% revenue decline in the third quarter.

Yahoo Finance
Aug 4th, 2026
Inspire Medical launches Project Horizon with $30M reinvestment to boost patient access amid reimbursement shifts

Inspire Medical Systems appointed AtriCure CEO Michael H. Carrel to its Board as director Casey M. Tansey plans to retire. The company reported quarterly revenue of $200.58 million and earnings of $0.14 per share, exceeding analyst expectations despite a year-on-year decline. Inspire raised its full-year outlook and launched Project Horizon, targeting $30 million in annualised investment capacity for patient access and education. The initiative comes alongside proposed reimbursement increases for its Inspire 5 procedure in 2027. The company's revenue narrative projects $987.4 million revenue and $67.1 million earnings by 2029. Investors are weighing the impact of Project Horizon against ongoing reimbursement and coding volatility affecting the firm's implant-based approach to obstructive sleep apnea treatment.

Yahoo Finance
Aug 3rd, 2026
Inspire Medical beats Q2 estimates with $200.6M revenue, raises full-year guidance to $855M

Inspire Medical Systems reported second-quarter revenue of $200.6 million, beating analyst estimates by 3% despite a 7.6% year-on-year decline. The medical technology company, which develops implantable devices for obstructive sleep apnea treatment, posted adjusted earnings per share of $0.14, significantly exceeding the consensus estimate of -$0.25. The company raised its full-year revenue guidance to $855 million at the midpoint, 1.4% above analyst expectations. Management also increased full-year adjusted EPS guidance to $1.25, a 25% rise. Adjusted EBITDA reached $38.9 million with a 19.4% margin, beating estimates by 40.5%. Following the results, Inspire Medical Systems' stock jumped 13.6%. CEO Tim Herbert attributed the performance to increased discipline whilst navigating evolving coding and reimbursement challenges.